BioSpace News Archive

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today a national distribution agreement with Genadyne Biotechnologies Inc. for its negative pressure wound therapy (“NPWT”) systems and supplies.

ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN) today presented preclinical data supporting the development of a computationally-derived amyloid-beta (Aβ) vaccine for AD at the American Academy of Neurology (AAN) 2023 Annual Meeting.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner Biogen has received U.S. Food and Drug Administration (FDA) approval of QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

AGC Biologics announced it has received the “Bioprocessing Excellence in Japan” award at the Asia-Pacific Bioprocessing Excellence Awards ceremony for the work and achievements at the AGC Biologics Chiba, Japan site.

J INTS BIO announced the poster presentation of its novel, orally administered TKI ‘JIN-A04' targeting NSCLC with HER2 exon 20 insertion mutation at the annual meeting of the American Association of Cancer Research 2023, which was held in Orlando, USA from April 14 to 19.

NanoViricides, Inc. reports that it is exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company’s COVID clinical drug candidate.

MolecuLight Inc. announced the publication of “Skin Pigmentation Impacts the Clinical Diagnosis of Wound Infection: Imaging of Bacterial Burden to Overcome Diagnostic Limitations"1 in the Journal of Racial and Ethnic Health Disparities.

Arch Therapeutics, Inc. announced that the Company will be exhibiting its AC5® Advanced Wound System at the Symposium on Advanced Wound Care Spring 2023, which takes place at National Harbor, MD from April 26-30, 2023.

Atea Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to bemnifosbuvir for the treatment of COVID-19.

ALX Oncology Holdings Inc. today announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a next generation CD47 blocker, and SARCLISA.